Interpretation of guidance for establishing the performance characteristics of in vitro diagnostic devices for the detection or detection and differentiation of high-risk human papillomaviruses issued by Food and Drug Administration of United States and China
10.3760/cma.j.issn.0253-3766.2017.07.016
- VernacularTitle: 高危型人乳头瘤病毒核酸体外检测试剂盒临床功能验证的中美指导原则解读
- Author:
Ruimei FENG
1
;
Wen CHEN
1
;
Youlin QIAO
1
Author Information
1. Department of Epidemiology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100021, China
- Publication Type:Journal Article
- Keywords:
Human papillomavirus;
Guidline;
Evaluation of nucleic acid detection;
Clinical performance evaluation
- From:
Chinese Journal of Oncology
2017;39(7):553-557
- CountryChina
- Language:Chinese
-
Abstract:
To establish the standardization of clinical verification designs for in vitro diagnostic devices(IVDs) of human papillomavirus, China Food and Drug Administration (CFDA) and United States Food and Drug Administration (FDA) issued guidelines of detailed study designs and effectiveness evaluation for accuracy validation and clinical performance of nucleic acid detection, respectively, including triage of a typical squamous cells of undetermined significance(ASC-US) patients and validation of combined screening and preliminary screening. The design, study population, sample size estimation and statistical analysis of guidelines were moderately different from America to China, however, the evaluation indication was similar. According to the guideline issued by CFDA, prospective design suggested by FDA could be replaced by cross sectional study design to validate the triage of ASC-US patients. Alternatively, prospective design could be used to conduct the HPV product declaration and cellular parallel detection for the same natural population, and the clinical effectiveness of declared products could be validated by at least 3 years follow-up of cytology.
